NCT00234637View on ClinicalTrials.gov

Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Alzheimer's Disease
Interventions
DRUG

Rivastigmine, memantine

Trial Locations (1)

87042

Département de Gérontologie Clinique, Limoges

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00234637 - Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment | Biotech Hunter | Biotech Hunter